1. Measured by its binding ability in a functional ELISA. 2. Immobilized mouse ApoAI at 10 μg/mL (100 μl/well) can bind  biotinylated human SCARB1, The EC50 of biotinylated human SCARB1 is 0.27 μg/mL.

Apolipoprotein A-I/APOA1 Protein, Mouse, Recombinant (aa 1-264, hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 55.8 kDa and the accession number is Q00623.

Mouse

HEK293 Cells

apolipoprotein A-I,Apoa-1,Ltw-1,Brp-14,apo-AI,42249,apoA-I,Alp-1,42248,Lvtw-1

The Mouse APOA1 (Q00623) (Met 1-Gln 264) was fused with the Fc region of Human IgG1 at the C-terminus.

> 90 % as determined by SDS-PAGE

A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Apolipoprotein A1 (APOA1) is a member of the apolipoprotein family whose members are proteins bind with lipids and form lipoproteins to translate these oil-soluble lipids such as fat and cholesterol through lymphatic and circulatory system. APOA1 is the main component of high density lipoprotein (HDL) in plasma and is involved in the esterification of cholesterol as a cofactor of lecithin-cholesterol acyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters, and thus play a major role in cholesterol efflux from peripheral cells. As a major component of the HDL complex, APOA1 helps to clear cholesterol from arteries. APOA1 is also characterized as a prostacyclin stabilizing factor, and thus may have an anticlotting effect. Defects in encoding gene may result in HDL deficiencies, including Tangier disease, and with systemic non-neuropathic amyloidosis. Men carrying a mutation may develop premature coronary artery disease.